The UK’s National Institute
for Health and Care Excellence
(NICE) has issued new draft
guidance recommending Xtandi
(enzalutamide) as a treatment
option for hormone relapsed
metastatic prostate cancer in
adults.
Enzalutamide works in a
different way to other drugs
currently available for treating
prostate cancer and NICE plans to
recommend it as an option only
under specific circumstances.
To read the full details of the draft
guidance, CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 30 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Jan 14
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.